Lunai Bioworks Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Shareholders held on October 31, 2025. Lunai Bioworks Inc. (Nasdaq: LNAI) is a Delaware corporation with principal executive offices in Los Angeles, CA. The filing details the outcomes of four shareholder proposals regarding corporate governance, executive compensation, auditor ratification, and equity incentives.
Key Financial Metrics
This filing is a Current Report regarding corporate governance events and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
Shareholders approved all four proposals submitted at the Annual Meeting. The specific vote tallies were as follows:
- Proposal 1 (Election of Directors): All four nominees (David Weinstein, James McNulty, Douglas W. Calder, Mark A. Collins) were elected. Total votes "For" ranged from approximately 7.34 million to 7.54 million per nominee. There were 1,314,903 Broker Non-Votes.
- Proposal 2 (Say-on-Pay): Approved with 5,548,091 votes "For" versus 2,182,131 "Against" and 11,760 "Abstain".
- Proposal 3 (Auditor Ratification): Sadler, Gibb & Associates LLC was ratified as the independent auditor with 8,836,759 votes "For" versus 18,002 "Against".
- Proposal 4 (Equity Incentive Plan Amendments): Amendments to the Renovaro Biosciences, Inc. 2023 Equity Incentive Plan were approved with 6,956,477 votes "For" versus 574,336 "Against".
Guidance, Outlook, and Risks
The filing contains no management commentary on financial guidance, future outlook, or specific risk factors. It confirms that the election of directors complied with Nasdaq Listing Rule 5605(e) and applicable corporate governance standards.
Investor Verification Checklist
- Verify the specific terms of the amendments to the 2023 Equity Incentive Plan referenced in Annex A of the proxy statement.
- Review the full proxy statement for details on the "Say-on-Pay" compensation metrics that received shareholder approval.
- Confirm the independence status of the newly elected directors as required by Nasdaq rules.
- Check subsequent filings (10-K or 10-Q) for the actual financial performance metrics, as this 8-K does not include them.